SCHEMBL4706434

SCHEMBL4706434

Clc1ccc2c(c1)Nc1cc(Cl)c(Cl)cc1S2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 10/20 0.68
BCHE P06276 3/20 0.68
ACHE P22303 3/20 0.68
GAA P10253 4/20 0.45
MAPT P10636 4/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
MAPK13 O15264 1/20 0.43
DAPK3 O43293 1/20 0.43
ROCK2 O75116 1/20 0.43
CHEK2 O96017 1/20 0.43
PIM1 P11309 1/20 0.43
CDK2 P24941 1/20 0.43
RECQL P46063 1/20 0.43
GSK3A P49840 1/20 0.43
GSK3B P49841 1/20 0.43
CSNK2A1 P68400 1/20 0.43
PRKCZ Q05513 1/20 0.43
PRKAA1 Q13131 1/20 0.43
ROCK1 Q13464 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28117966 0.90 NOX1 (0.81) NOX1BCHEACHEGAAMAPT
SCHEMBL4708136 0.89 NOX1 (0.58) NOX1BCHEACHEGAAMAPT
SCHEMBL28117917 0.86 NOX1 (0.76) NOX1BCHEACHEGAAMAPT
SCHEMBL4706870 0.85 NOX1 (0.45) NOX1BCHEACHEGAAMAPT
SCHEMBL236458 0.81 NOX1 (1.00) NOX1BCHEACHEGAAMAPT
SCHEMBL29384266 0.81 NOX1 (1.00) NOX1BCHEACHEGAAMAPT
SCHEMBL28679021 0.79 NOX1 (0.96) NOX1BCHEACHEGAAMAPT
SCHEMBL28232162 0.79 NOX1 (0.96) NOX1BCHEACHEGAAMAPT
SCHEMBL28635096 0.79 NOX1 (0.65) NOX1BCHEACHEGAAMAPT
SCHEMBL1855994 0.79 NOX1 (0.65) NOX1BCHEACHEGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765797-A4 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE UNIV KANSAS CT FOR RES INC (US) 2008-02-06 EP claimed
EP-1765797-A1 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE University of Kansas Center for Research, Inc. (US) 2007-03-28 EP claimed
WO-2006002441-A1 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE UNIVERSITY OF KANSAS (US) 2006-01-05 WO claimed
US-20050288279-A1 Phenothiazine derivatives and their method of use KANSAS MEDICAL CENTER, UNIVERSITY OF 2005-12-29 US claimed
EP-1765797-A4 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE UNIV KANSAS CT FOR RES INC (US) 2008-02-06 EP disclosed
EP-1765797-A1 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE University of Kansas Center for Research, Inc. (US) 2007-03-28 EP disclosed
WO-2006002441-A1 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE UNIVERSITY OF KANSAS (US) 2006-01-05 WO disclosed
US-20050288279-A1 Phenothiazine derivatives and their method of use KANSAS MEDICAL CENTER, UNIVERSITY OF 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288279-A1 Phenothiazine derivatives and their method of use SHBG, GPR119, BRDT NOX1 3177/4885BCHE 3057/4885ACHE 2804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.